# A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

> **NCT03693625** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Urticaria

## Interventions

- **DRUG:** GDC-0853

## Key facts

- **NCT ID:** NCT03693625
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-27
- **Primary completion:** 2019-10-23
- **Final completion:** 2019-10-23
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Recruitment was stopped after an interim analysis of the parent GS39684 study.
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03693625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03693625, "A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03693625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*